Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

CERE

Cerevel Therapeutics (CERE)

Cerevel Therapeutics Holdings Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CERE
DateHeureSourceTitreSymboleSociété
08/05/202422h17Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CERECerevel Therapeutics Holdings Inc
18/04/202412h30GlobeNewswire Inc.Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s DiseaseNASDAQ:CERECerevel Therapeutics Holdings Inc
27/02/202422h02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CERECerevel Therapeutics Holdings Inc
16/02/202422h46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CERECerevel Therapeutics Holdings Inc
09/02/202415h00Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CERECerevel Therapeutics Holdings Inc
09/02/202401h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CERECerevel Therapeutics Holdings Inc
24/01/202414h30PR Newswire (US)Kuehn Law Encourages MDC, WAVD, NS and CERE Investors to Contact Law FirmNASDAQ:CERECerevel Therapeutics Holdings Inc
18/01/202413h44Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:CERECerevel Therapeutics Holdings Inc
18/01/202413h19Edgar (US Regulatory)Form PRER14A - Preliminary Proxy Soliciting materialsNASDAQ:CERECerevel Therapeutics Holdings Inc
05/01/202423h13Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:CERECerevel Therapeutics Holdings Inc
03/01/202400h10PR Newswire (US)Kuehn Law Encourages CERE, HA, IMGN, and WAVD Investors to Contact Law FirmNASDAQ:CERECerevel Therapeutics Holdings Inc
26/12/202323h03Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CERECerevel Therapeutics Holdings Inc
08/12/202323h00Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:CERECerevel Therapeutics Holdings Inc
08/12/202312h23IH Market NewsApple Boosts Vietnam Production, Broadcom Revenue Miss, Stellantis Job Cuts – Latest UpdatesNASDAQ:CERECerevel Therapeutics Holdings Inc
07/12/202312h23IH Market NewsAlphabet Unveils Advanced AI Model, AMD Expects $45 Billion AI Market, Chevron’s $19.5B Investment Plans, BMY Increases Dividend, and MoreNASDAQ:CERECerevel Therapeutics Holdings Inc
07/12/202305h24PR Newswire (US)CERE MERGER ANNOUNCEMENT: Julie & Holleman LLP Announces Investigation Into Potential Claims Regarding AbbVie's Proposed Acquisition of Cerevel TherapeuticsNASDAQ:CERECerevel Therapeutics Holdings Inc
06/12/202322h30PR Newswire (US)AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience PipelineNASDAQ:CERECerevel Therapeutics Holdings Inc
29/11/202312h30GlobeNewswire Inc.Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s DiseaseNASDAQ:CERECerevel Therapeutics Holdings Inc
08/11/202312h30GlobeNewswire Inc.Cerevel Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:CERECerevel Therapeutics Holdings Inc
01/11/202311h30GlobeNewswire Inc.Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business UpdatesNASDAQ:CERECerevel Therapeutics Holdings Inc
13/10/202312h30GlobeNewswire Inc.Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023NASDAQ:CERECerevel Therapeutics Holdings Inc
12/10/202322h16Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CERECerevel Therapeutics Holdings Inc
12/10/202304h45GlobeNewswire Inc.Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common StockNASDAQ:CERECerevel Therapeutics Holdings Inc
11/10/202322h01GlobeNewswire Inc.Cerevel Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:CERECerevel Therapeutics Holdings Inc
29/08/202312h30GlobeNewswire Inc.Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare ConferenceNASDAQ:CERECerevel Therapeutics Holdings Inc
02/08/202312h30GlobeNewswire Inc.Cerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business UpdatesNASDAQ:CERECerevel Therapeutics Holdings Inc
05/07/202312h30GlobeNewswire Inc.Cerevel Therapeutics to Report Second Quarter 2023 Financial Results and Business Updates on Wednesday, August 2, 2023NASDAQ:CERECerevel Therapeutics Holdings Inc
29/06/202301h00Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:CERECerevel Therapeutics Holdings Inc
15/06/202322h37Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:CERECerevel Therapeutics Holdings Inc
15/06/202312h30GlobeNewswire Inc.Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations OfficerNASDAQ:CERECerevel Therapeutics Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:CERE